Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Headline outcomes only

No studies found 2 · 33.3%GRADE not reported 0 · 0%Very low 3 · 50%Low 0 · 0%Moderate 1 · 16.7%High 0 · 0%

Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease

High dose 5‐ASA showed no clear difference in endoscopic recurrence compared with low dose 5‐ASA (moderate certainty).

1 finding from 1 review

Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease

It is very uncertain whether 5‐ASA changes endoscopic recurrence compared with purine antimetabolites (very low certainty).

1 finding from 1 review

Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease

It is very uncertain whether 5‐ASAs changes endoscopic recurrence compared with anti TNF‐ɑ (very low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 13.33 [1.98, 89.95]
1 study · 34 participants
Very low

Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease

It is very uncertain whether 5‐ASAs changes endoscopic recurrence compared with placebo (very low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.83 [0.56, 1.24]
3 studies · 537 participants
Very low